OTTAVA's automation isn't autonomy yet. Here's where it actually sits.
- 9 hours ago
- 3 min read
Every surgeon who has fought a boom-mounted robot for OR space knows the real cost of setup time. It is not the minutes on the clock. It is the variability: a system that behaves differently depending on which fellow is calibrating it that morning, and a surgical team that has to keep its most experienced hands in the room just to get the arms positioned.
That is the problem Johnson & Johnson is solving with OTTAVA, the table-integrated soft tissue robotic system that received FDA De Novo authorization on July 22, 2026. It is also, specifically, not the problem of surgical autonomy. Those are two different engineering problems, and the language coming out of J&J this month blurs them in a way worth pulling apart.
What the automation actually does
Rocco De Bernardis, Global President of the OTTAVA program, described the system's setup process directly: OTTAVA uses automated procedure poses tied to the specific operation and patient, with no calibration or registration step. Press a button, and the arms move to roughly 90 percent of their final position on their own.
The second headline feature, Twin Motion, synchronizes the operating table and the robotic arms so the surgical team can reposition the patient mid-procedure without undocking the system or pausing to recalibrate.
Both are real engineering achievements. Neither one makes a clinical decision. A surgeon still identifies the anatomy, still drives every cut, still owns every judgment call in the case. What OTTAVA automates is logistics: the mechanical choreography around the surgeon, not the surgery itself.
On the autonomy ladder, that places OTTAVA's launch capabilities firmly at Level 1. Task automation, fully surgeon-directed, zero independent decision-making. It is a meaningful step up from boom-based systems that require manual setup at every stage. It is not a step toward a robot that recognizes tissue planes or flags a bleed on its own.
The more interesting signal is the data platform
De Bernardis was clear that the automation on offer at launch is only part of the plan. OTTAVA connects to J&J's Polyphonic digital ecosystem, which the company describes as an open, secure platform pulling data from J&J devices and non-J&J devices in the operating room alike.
Asked about that ecosystem, De Bernardis said the company is open to third-party surgical innovators using that data to build automation, AI, and new algorithms of their own. In his words, Polyphonic is meant to function as "a platform for innovation" beyond OTTAVA's own feature set.
That is the detail that matters more than the launch-day automation claims. J&J is not promising an autonomous robot. It is building the data infrastructure that would let someone else's algorithm climb the ladder on top of J&J's hardware, on J&J's terms, inside J&J's ecosystem.
Why the company is being careful about the word
At the August 3 investor call following the FDA authorization, Neda Cvijetic, Global Head of R&D for Robotics and Digital, described OTTAVA's architecture as a foundation for continued automation, software, and digital development. She paired that claim with a deliberate emphasis: the company's approach is designed to keep surgeons and care teams in control.
That pairing is not accidental. A soft tissue robot entering a market still dominated by one competitor cannot afford a safety incident tied to overpromised autonomy claims, particularly in general surgery procedures as complex as the Roux-en-Y gastric bypass cases in OTTAVA's FORTE trial. That 30-patient study met its primary safety and performance endpoints through 30 days post-procedure, with every procedure completed robotically and no conversions to an open or laparoscopic approach.
Strong results, and J&J is right to protect them by keeping the autonomy claims modest for now.
What to actually watch
The launch features are not where OTTAVA's autonomy story will be written. The Polyphonic platform is. If third-party developers start shipping algorithms on top of that data layer, that is the signal that OTTAVA is climbing past Level 1, not another press release about automated procedure poses.
For now, hospitals evaluating OTTAVA should treat it as what it is: a genuinely space-efficient, workflow-automated platform with an open architecture built for a more autonomous future. That future has not arrived yet, and J&J has been careful, correctly, not to claim that it has.
